Genprex
GNPX
13 hedge funds and large institutions have $247K invested in Genprex in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 0 closing their positions.
210% more capital invested
Capital invested by funds: $79.7K → $247K (+$167K)
30% more funds holding
Funds holding: 10 → 13 (+3)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$70.8K |
| 2 |
VF
Virtu Financial
New York
|
+$36.7K |
| 3 |
Goldman Sachs
New York
|
+$31.5K |
| 4 |
Morgan Stanley
New York
|
+$10.5K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$59K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$7.86K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$5.24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.93K |
| 5 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
-$145 |
GNPX Hedge Fund Activity: Q4 2024 in Review
13 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q4 2024, worth a combined $247K — up 210% from $79.7K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GNPX positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $70.8K. The largest seller was UBS Group, cutting an estimated $59K.
- 13 institutional investors held Genprex (GNPX) as of Q4 2024, up from 10 in Q3 2024.
- Funds reported $247K of Genprex stock for Q4 2024, up 210% quarter-over-quarter.
- 3 funds opened new Genprex positions in Q4 2024 and 0 closed out, a net change of +3 holders.
- The largest Genprex buyer in Q4 2024 was Geode Capital Management, an estimated $70.8K added.
- The largest Genprex seller in Q4 2024 was UBS Group, an estimated $59K sold.
Based on aggregated 13F filings for Q4 2024.